1,359 results match your criteria: "Albert Schweitzer Hospital[Affiliation]"

Background: This study evaluated the safety and efficacy of BioMime sirolimus-eluting stent (SES) system, with an ultra-low strut thickness (65 µm), in real-world all-comers population with coronary artery stenosis (CAD).

Methods: This was a post-marketing, multicenter, single-arm, observational clinical registry among patients undergoing intervention for CAD. Patients were clinically followed up at 1, 9, 12, and 24 months after the index percutaneous coronary intervention.

View Article and Find Full Text PDF

Importance: Efficient care processes are crucial to minimize treatment delays and improve outcome after endovascular thrombectomy (EVT) in patients with ischemic stroke. A potential means to improve care processes is performance feedback.

Objective: To evaluate the effect of performance feedback to hospitals on treatment times for EVT.

View Article and Find Full Text PDF

Background: Previous spontaneous preterm birth (sPTB) is a strong risk indicator for recurrent preterm birth (PTB). Cervical cerclage is an accepted intervention to prevent recurrent PTB in high risk patients. Cervical pessary might be a less invasive alternative.

View Article and Find Full Text PDF

Background And Study Aims: Piecemeal EMR of large (≥20mm) non-pedunculated colorectal polyps (LNPCPs) is succeeded by a 6-month surveillance endoscopy to evaluate the post-EMR scar for recurrence. Data from expert centers suggest that routine tattoo placement and scar biopsies can be omitted, but data from community hospitals are lacking.

Patients And Methods: In a post-hoc analysis of the STAR-LNPCP study (NTR7477), containing prospective data on 6-month post-pEMR scar assessments in 30 Dutch community hospitals (October 2019 to May 2022), the agreement between optical assessment and histological confirmation by routine biopsies was evaluated.

View Article and Find Full Text PDF

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

N Engl J Med

December 2024

From Alexandra General Hospital, National and Kapodistrian University of Athens, Athens (M.A.D.); Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC (P.M.V.); Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo (F.S.); Tel-Aviv Sourasky (Ichilov) Medical Center and Tel Aviv University, Tel Aviv, Israel (Y.C.C.); Clínica Medica São Germano, São Paulo (V.H.); Cross Cancer Institute, University of Alberta, Edmonton, Canada (I. Sandhu); Kent and Canterbury Hospital, Canterbury, United Kingdom (J.L.); Perth Blood Institute, Murdoch University, Perth, WA, Australia (R.I.B.); Japanese Red Cross Medical Center, Tokyo (K.S.); Ogaki Municipal Hospital, Ogaki City, Japan (H.K.); Albert Schweitzer Hospital, Dordrecht, the Netherlands (M.-D.L.); Ankara University, Ankara, Turkey (M.B.); Washington University School of Medicine, St. Louis (K.S.-G.); Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona (A.O.); South Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, Hungary (G.M.); Hospital Alemán, Buenos Aires (G.G.); Jessa Hospital, Hasselt, Belgium (K.T.); Charles University and General Hospital, Prague, Czech Republic (I. Spicka); Rigshospitalet, University of Copenhagen, Copenhagen (A.K.M.); SSD Clinical Trials in Oncol-ematologia e Mieloma Multiplo, AOU Città della Salute e della Scienza di Torino, Turin, Italy (S.B.); Medical Unit Hematology, Karolinska University Hospital, Stockholm (K.U.); Institute of Hematology and Transfusion Medicine, Warsaw, Poland (B.P.); Knight Cancer Institute, Oregon Health and Science University, Portland (E.M.); University of Washington and Fred Hutchinson Cancer Center, Seattle (A.J.C.); University Hospital Hôtel-Dieu, Nantes, France (P.M.); University Hospital of Salamanca, IBSAL, and Cancer Research Center, IBMCC, Salamanca, Spain (M.-V.M.); GMMG Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany (H.G.); Genmab US, Plainsboro, NJ (T.A.); Janssen Research and Development, Shanghai, China (L.S., L.L.); Janssen Scientific Affairs, Horsham, PA (A.C.); Janssen Research and Development, Raritan, NJ (E.G.K., R.M.D.); Janssen Research and Development, Beerse, Belgium (E.R.); Janssen Research and Development, Spring House, PA (R.C.); and Mayo Clinic, Rochester, MN (S.V.R.).

Background: Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma, a precursor disease of active multiple myeloma for which no treatments have been approved.

Methods: In this phase 3 trial, we randomly assigned patients with high-risk smoldering multiple myeloma to receive either subcutaneous daratumumab monotherapy or active monitoring.

View Article and Find Full Text PDF

Importance: Increasing numbers of people with multiple sclerosis (MS) use disease-modifying therapy (DMT). Long-term stable disease while taking such medications provides a rationale for considering DMT discontinuation given patient burden, costs, and potential adverse effects of immunomodulating therapy.

Objective: To investigate whether first-line DMT can be safely discontinued in patients with long-term stable MS.

View Article and Find Full Text PDF

Background: Alemtuzumab can be an alternative to rabbit anti-thymocyte globulin (rATG) to treat severe or glucocorticoid-resistant acute T cell-mediated kidney transplant rejection (TCMR). Yet, there are few reports in which these two treatments are evaluated let alone, compared. This study describes the real-world clinical experience of both therapies and compares their efficacy and toxicity.

View Article and Find Full Text PDF

Caesarean scar pregnancy complicated by partial rupture in the second trimester: A case report.

Case Rep Womens Health

December 2024

Department of Obstetrics and Gynaecology, Albert Schweitzer hospital, Albert Schweitzerplaats 25, 3318 AT Dordrecht, the Netherlands.

This case report examines caesarean scar pregnancy, a rare but significant complication associated with increasing global caesarean rates. It explores diagnostic challenges, therapeutic interventions, and the importance of a multidisciplinary approach. This report details the case of a patient at 13 + 4 weeks of amenorrhea presenting with severe abdominal pain, diagnosed with caesarean scar pregnancy and scar dehiscence causing major haemorrhage.

View Article and Find Full Text PDF
Article Synopsis
  • - BCR::ABL1 digital PCR is a highly sensitive and precise method for measuring deep molecular responses in chronic myeloid leukemia, outperforming traditional qPCR, especially in predicting successful treatment-free remission.
  • - In a study with 168 patient samples, digital PCR demonstrated better detection capabilities, quantifying BCR::ABL1 in 68% of cases that were below the detection limit of qPCR, which required a high number of transcripts.
  • - The technique also allowed for differentiation between BCR::ABL1 transcript types, making it a practical and effective option for clinical use in monitoring treatment responses.
View Article and Find Full Text PDF

Evaluation of the recently established Dutch nationwide Archipelago of Ovarian Cancer Research biobank.

Ann Diagn Pathol

February 2025

Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands. Electronic address:

Fundamental and translational research in ovarian cancer aims to enhance understanding of disease mechanisms and improve treatment and survival outcomes. To support this, we established the Dutch multicenter, interdisciplinary Archipelago of Ovarian Cancer Research (AOCR) infrastructure, which includes a nationwide biobank. In this study, we share our experiences in establishing the infrastructure, offer guidance for similar initiatives, and evaluate the AOCR patient cohort.

View Article and Find Full Text PDF
Article Synopsis
  • The IMWG frailty index shows that frailty levels in patients undergoing anti-myeloma treatment can change frequently over time.
  • Assessing frailty dynamically during treatment provides better predictions for survival and early mortality than just looking at initial frailty levels.
  • The study references two clinical trials, HOVON 143 (NTR6297) and HOVON 123 (NTR4244), related to this research.
View Article and Find Full Text PDF

Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population-based study in the Netherlands, 1996-2020.

Hemasphere

November 2024

Department of Research and Development Netherlands Comprehensive Cancer Organisation (IKNL) Utrecht The Netherlands.

Chronic lymphocytic leukemia (CLL) manifests heterogeneously with varying outcomes. This population-based study examined causes of death (CODs), as registered by the physician who established the death, among 20,588 CLL patients diagnosed in the Netherlands between 1996 and 2020. Utilizing cause-specific flexible parametric survival models, we estimated cause-specific hazard ratios (HRs) and cumulative incidences of death due to CLL, solid malignancies, other hematological malignancies, infections, and other causes.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the impact of non-culprit (NC) lesions in patients with NSTEMI compared to those with STEMI, focusing on high-risk plaque features and their influence on clinical outcomes.
  • Among 438 patients, both NSTEMI and STEMI groups showed similar prevalence of high-risk plaques, but NSTEMI patients had a higher rate of major adverse cardiovascular events (MACE) after two years.
  • The findings suggest that the presence of high-risk plaques in NC lesions is critical for dictating future cardiovascular events, indicating the need for further research on effective revascularization strategies in NSTEMI patients.
View Article and Find Full Text PDF
Article Synopsis
  • - This study aimed to explore how depression and anxiety impact the ability of rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients to achieve disease remission, as well as how these mental health symptoms interact with various aspects of disease activity.
  • - Researchers assessed 400 RA patients and 367 PsA patients over two years, finding that high levels of anxiety and depression were linked to a lower chance of remission, especially depression when controlled for anxiety symptoms.
  • - The results indicated that patients showing signs of depression or anxiety had worse overall health and more pain, pointing to the need for healthcare professionals to pay close attention to mental health in patients with RA and PsA.
View Article and Find Full Text PDF

Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years.

Pharmacoecon Open

October 2024

Department of Cardiology, Thoraxcentrum Twente, Medisch Spectrum Twente, Koningsplein 1, 7512 KZ, Enschede, The Netherlands.

Background And Objective: Evidence on health economic outcomes for percutaneous coronary intervention (PCI) comparing different contemporary drug-eluting stents (DES) with each other is scarce, as most previous randomised DES trials did not assess such aspects. This prespecified health economic evaluation of the Comparison of Biodegradable Polymer and Durable Polymer Drug-Eluting Stents in an All Comers Population (BIO-RESORT) trial aimed to compare at 3-year follow-up both health effects and costs of PCI with one of three new-generation drug-eluting stents (DES) in patients with obstructive coronary artery disease.

Methods: The randomised BIO-RESORT trial assessed in 3514 patients the ultrathin-strut biodegradable polymer Orsiro sirolimus-eluting stent (SES) and very-thin-strut Synergy everolimus-eluting (EES) stent versus the thin-strut durable polymer Resolute Integrity zotarolimus-eluting stent (ZES).

View Article and Find Full Text PDF

Objectives: The widespread adoption of wearables, for example, smartphones and smartwatches in the daily lives of the general population, allows passive monitoring of physiological and behavioural data in the real world. This qualitative study explores the perspective of psoriatic arthritis (PsA) patients towards these so-called digital biomarkers (dBMs).

Methods: As part of a Design Thinking approach, six focus groups were conducted involving 27 PsA patients.

View Article and Find Full Text PDF
Article Synopsis
  • A significant portion of patients (1 in 10) experience epilepsy after having cerebral venous thrombosis (CVT), but it's challenging to predict who will be affected.* -
  • Researchers created the DIAS3 prognostic score using clinical data from over 1,100 patients to assess the likelihood of developing post-CVT epilepsy based on six clinical variables.* -
  • The study found a range of predicted risks for post-CVT epilepsy within one and three years, with successful validation of the score confirming its effectiveness in estimating individual risk.*
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate if a combination of patient-reported outcomes related to health, disability, pain, quality of life, and fatigue could help detect active disease in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients.
  • Researchers analyzed data from 683 RA patients and 525 PsA patients, measuring the correlation between changes in these outcomes and clinically defined active disease.
  • Results showed that declines in general health, disability, quality of life, and pain were significantly linked to active disease, indicating that this combination of measures could effectively serve as a screening tool for monitoring these conditions remotely.
View Article and Find Full Text PDF
Article Synopsis
  • * This review analyzes factors influencing the choice between active (Osia System) and passive (Baha Connect System) bone-conduction devices based on expert feedback from surveys and discussions.
  • * Key decision-making factors include surgical requirements, bone thickness, MRI compatibility, patient preferences, and risks like skin infections, emphasizing the need for personalized consultations in multidisciplinary settings.
View Article and Find Full Text PDF